Cosmos Health enters exclusive license for two cancer-treatment patents; up to EUR 7.5M buy-out

Cosmos Health Inc.

Exclusive worldwide license for two patents (filed 2016, 2017) to treat cancer; commercialize via R&D and trials.
Initial payment $500K by Dec 31, 2024; fixed EUR 350K/year 2025-2030; thereafter 1.5% of Net Sales.
Buy-out option to acquire patents for total EUR 7,500,000 (EUR 4M for Patent 1, EUR 3.5M for Patent 2).
Licensor DocPharma is a related party; agreement governed by New York law; term for life of patents or 20 years.
Cosmos has right to sublicense and terminate for convenience after 5 years; Licensor can terminate for uncured breach.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.